StocksMedium•13 October 2026•
1 min read
Alaunos Therapeutics Acquires Velaris; Paragon Labs Expands Leadership
Key Facts
1Alaunos Therapeutics acquired Velaris Therapeutics, a biotechnology company focused on pulmonary hypertension.
2Former senior leadership from Apogee Therapeutics joined Paragon Labs to support drug development and company building.
3Velaris is the ninth company launched around assets discovered by Paragon Labs.
Alaunos Therapeutics acquired Velaris Therapeutics, a biotechnology company focused on pulmonary hypertension. PR Newswire reported that Velaris is the ninth company launched around assets discovered by Paragon Labs, aiming to accelerate the development of therapeutic candidates for cardiopulmonary diseases.
Former senior leadership from Apogee Therapeutics joined Paragon Labs to support company building and drug development following the acquisition of Apogee by AbbVie. In equity markets, TCRT closed at $1.05 on October 12, 2026, while ABBV closed at $281.12 on the same date.